CN102762207A - 用于治疗神经精神疾患的nmda受体拮抗剂 - Google Patents

用于治疗神经精神疾患的nmda受体拮抗剂 Download PDF

Info

Publication number
CN102762207A
CN102762207A CN2009801184245A CN200980118424A CN102762207A CN 102762207 A CN102762207 A CN 102762207A CN 2009801184245 A CN2009801184245 A CN 2009801184245A CN 200980118424 A CN200980118424 A CN 200980118424A CN 102762207 A CN102762207 A CN 102762207A
Authority
CN
China
Prior art keywords
alkyl
compound
independently
aralkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801184245A
Other languages
English (en)
Chinese (zh)
Inventor
雷蒙德·J·汀莱蒂尼
斯蒂芬·F·泰纳利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CN102762207A publication Critical patent/CN102762207A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801184245A 2008-05-09 2009-05-11 用于治疗神经精神疾患的nmda受体拮抗剂 Pending CN102762207A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12709808P 2008-05-09 2008-05-09
US61/127,098 2008-05-09
PCT/US2009/043502 WO2009137843A2 (en) 2008-05-09 2009-05-11 Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
CN102762207A true CN102762207A (zh) 2012-10-31

Family

ID=41265475

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801184245A Pending CN102762207A (zh) 2008-05-09 2009-05-11 用于治疗神经精神疾患的nmda受体拮抗剂

Country Status (16)

Country Link
US (1) US20110160223A1 (enExample)
EP (1) EP2296658A4 (enExample)
JP (1) JP2011520815A (enExample)
KR (1) KR20110016891A (enExample)
CN (1) CN102762207A (enExample)
AU (1) AU2009244082A1 (enExample)
BR (1) BRPI0912362A2 (enExample)
CA (1) CA2722776A1 (enExample)
CO (1) CO6341558A2 (enExample)
EA (1) EA020339B1 (enExample)
IL (1) IL208895A0 (enExample)
MX (1) MX2010012186A (enExample)
NZ (1) NZ589764A (enExample)
SG (1) SG195568A1 (enExample)
WO (1) WO2009137843A2 (enExample)
ZA (1) ZA201007958B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071394A1 (zh) * 2017-10-09 2019-04-18 华南农业大学 一种抗白色念珠菌的新型化合物及其制备方法和应用
CN114539129A (zh) * 2020-11-18 2022-05-27 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762554A (zh) 2010-02-16 2012-10-31 辉瑞大药厂 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
AU2014243773B2 (en) 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
WO2014210456A1 (en) 2013-06-28 2014-12-31 Emory University Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3204011A4 (en) * 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
CA2991214C (en) 2015-07-06 2024-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11981652B2 (en) 2018-03-28 2024-05-14 Emory University GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
KR102793535B1 (ko) 2018-06-27 2025-04-11 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하는 방법
JP2022504036A (ja) 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害を治療するためのエスケタミンの投与計画
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2024533182A (ja) 2021-09-02 2024-09-12 エモリー ユニバーシティー 酸性ｐＨで増強された効力を有するＮ－メチル－Ｄ－アスパラギン酸受容体のＧｌｕＮ２Ｂサブユニット選択的アンタゴニスト

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005828B1 (de) * 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2824677A1 (de) * 1978-06-06 1979-12-20 Hoechst Ag Neue substituierte phenylpiperazinderivate und verfahren zu deren herstellung
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
DE3442570A1 (de) * 1984-11-22 1986-05-22 Hoechst Ag, 6230 Frankfurt Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
GB9005318D0 (en) * 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
CA2681877A1 (en) * 1997-10-31 1999-05-14 Asubio Pharma Co., Ltd. Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
WO2002028814A2 (en) * 2000-10-06 2002-04-11 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
DE10248925A1 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
HUP0401526A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use
AU2005277055B2 (en) * 2004-08-23 2011-03-31 Emory University Improved selection of-pH dependent compounds for in vivo therapy
JP2009500440A (ja) * 2005-07-12 2009-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性欲障害治療用医薬組成物
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
US7935706B2 (en) * 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
CN101815518B (zh) * 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071394A1 (zh) * 2017-10-09 2019-04-18 华南农业大学 一种抗白色念珠菌的新型化合物及其制备方法和应用
CN109803656A (zh) * 2017-10-09 2019-05-24 华南农业大学 一种抗白色念珠菌的新型化合物及其制备方法和应用
CN109803656B (zh) * 2017-10-09 2021-08-31 华南农业大学 一种抗白色念珠菌的化合物及其制备方法和应用
CN114539129A (zh) * 2020-11-18 2022-05-27 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途
CN114539129B (zh) * 2020-11-18 2023-06-09 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途

Also Published As

Publication number Publication date
US20110160223A1 (en) 2011-06-30
MX2010012186A (es) 2011-02-22
EP2296658A4 (en) 2014-01-15
WO2009137843A9 (en) 2010-03-11
CO6341558A2 (es) 2011-11-21
WO2009137843A2 (en) 2009-11-12
EA020339B1 (ru) 2014-10-30
BRPI0912362A2 (pt) 2015-10-06
EA201071291A3 (ru) 2014-02-28
IL208895A0 (en) 2011-01-31
KR20110016891A (ko) 2011-02-18
JP2011520815A (ja) 2011-07-21
CA2722776A1 (en) 2009-11-12
ZA201007958B (en) 2011-07-27
SG195568A1 (en) 2013-12-30
AU2009244082A1 (en) 2009-11-12
EP2296658A2 (en) 2011-03-23
EA201071291A2 (ru) 2011-04-29
NZ589764A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
CN102762207A (zh) 用于治疗神经精神疾患的nmda受体拮抗剂
CN101815518B (zh) 用于神经保护的nmda受体拮抗剂
US10351514B2 (en) Benzimidazole inhibitors of the sodium channel
CN108558831B (zh) 取代吡咯-4-烷基胺类化合物及其用途
CN107840845B (zh) 胺类化合物的新用途
CN105246887B (zh) 香豆素衍生物以及用于治疗过度增生性疾病的方法
JP2017538676A (ja) ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
JP7465868B2 (ja) 新規化合物
JP2014500882A (ja) カルシウム感知受容体活性化合物
TW202440561A (zh) 四氫噻吩衍生物及其在醫藥上的應用
US8680279B2 (en) Compounds for the treatment of neurological disorders
JP7522203B2 (ja) Ｋｖ３モジュレーター
RS54458B1 (sr) Derivati tieno [2,3-d]pirimidina i njihova primena u lečenju aritmije
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
JP2022506378A (ja) 疼痛及び疼痛に関連する状態を処置するための新規なテトラヒドロピリミドジアゼピン及びテトラヒドロピリドジアゼピン化合物
RU2830279C2 (ru) Новые соединения
AU2013203941A1 (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2024178425A1 (en) Hydroxyalkyl and methoxyalkyl tryptamines
CN117447455A (zh) 一种含氮杂环化合物
HK40059626B (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
HK40059626A (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
HK1146902B (en) Nmda receptor antagonists for neuroprotection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121031